First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastomaLinda M. Liau, Santosh Kesari, Keyoumars Ashkan et al.|Journal of Translational Medicine|2018Cited by 540
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent GlioblastomaLinda M. Liau, Lynne P. Taylor, Keyoumars Ashkan et al.|JAMA Oncology|2022Cited by 411
Genome-wide association study of intracranial aneurysm identifies three new risk lociKatsuhito Yasuno, Elío Vivas, Kaya Bilgüvar et al.|Nature Genetics|2010Cited by 318
ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMASMichael Platten, Wolfgang Wick, Martin Misch et al.|Neuro-Oncology|2018Cited by 26
A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).Michael Platten, Wolfgang Wick, Daniela Schilling et al.|Journal of Clinical Oncology|2018Cited by 25